These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37641398)

  • 1. Facilitated telemedicine for hepatitis C virus: Addressing challenges for improving health and life for people with opioid use disorder.
    Talal AH; Jaanimägi U; Dharia A; Dickerson SS
    Health Expect; 2023 Dec; 26(6):2594-2607. PubMed ID: 37641398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Care Integration for Hepatitis C Virus Treatment Through Facilitated Telemedicine Within Opioid Treatment Programs: Qualitative Study.
    Dickerson SS; George SJ; Ventuneac A; Dharia A; Talal AH
    J Med Internet Res; 2024 Jun; 26():e53049. PubMed ID: 38865703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engaging people who use drugs in clinical research: integrating facilitated telemedicine for HCV into substance use treatment.
    Talal AH; George SJ; Talal LA; Dharia A; Ventuneac A; Baciewicz G; Perumalswami PV; Dickerson SS
    Res Involv Engagem; 2023 Aug; 9(1):63. PubMed ID: 37533127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scaling and Sustaining Facilitated Telemedicine to Expand Treatment Access Among Underserved Populations: A Qualitative Study.
    Ventuneac A; Dickerson SS; Dharia A; George SJ; Talal AH
    Telemed J E Health; 2023 Dec; 29(12):1862-1869. PubMed ID: 37252770
    [No Abstract]   [Full Text] [Related]  

  • 5. High Satisfaction with Patient-Centered Telemedicine for Hepatitis C Virus Delivered to Substance Users: A Mixed-Methods Study.
    Talal AH; Sofikitou EM; Wang K; Dickerson S; Jaanimägi U; Markatou M
    Telemed J E Health; 2023 Mar; 29(3):395-407. PubMed ID: 35925809
    [No Abstract]   [Full Text] [Related]  

  • 6. Patient-centered HCV care via telemedicine for individuals on medication for opioid use disorder: Telemedicine for Evaluation, Adherence and Medication for Hepatitis C (TEAM-C).
    Talal AH; Markatou M; Sofikitou EM; Brown LS; Perumalswami P; Dinani A; Tobin JN
    Contemp Clin Trials; 2022 Jan; 112():106632. PubMed ID: 34813962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial for a peer-facilitated telemedicine hepatitis c treatment intervention for people who use drugs in rural communities: study protocol for the "peer tele-HCV" study.
    Herink MC; Seaman A; Leichtling G; Larsen JE; Gailey T; Cook R; Thomas A; Korthuis PT
    Addict Sci Clin Pract; 2023 May; 18(1):35. PubMed ID: 37245041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated Hepatitis C-Opioid Use Disorder Care Through Facilitated Telemedicine: A Randomized Trial.
    Talal AH; Markatou M; Liu A; Perumalswami PV; Dinani AM; Tobin JN; Brown LS
    JAMA; 2024 Apr; 331(16):1369-1378. PubMed ID: 38568601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of an mHealth Intervention on Hepatitis C Testing Uptake Among People With Opioid Use Disorder: Randomized Controlled Trial.
    Hochstatter KR; Gustafson DH; Landucci G; Pe-Romashko K; Cody O; Maus A; Shah DV; Westergaard RP
    JMIR Mhealth Uhealth; 2021 Feb; 9(2):e23080. PubMed ID: 33616545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient Reaction to Telemedicine for Clinical Management of Hepatitis C Virus Integrated into an Opioid Treatment Program.
    Talal AH; McLeod A; Andrews P; Nieves-McGrath H; Chen Y; Reynolds A; Sylvester C; Dickerson SS; Markatou M; Brown LS
    Telemed J E Health; 2019 Sep; 25(9):791-801. PubMed ID: 30325701
    [No Abstract]   [Full Text] [Related]  

  • 11. A novel mHealth application for improving HIV and Hepatitis C knowledge in individuals with opioid use disorder: A pilot study.
    Ochalek TA; Heil SH; Higgins ST; Badger GJ; Sigmon SC
    Drug Alcohol Depend; 2018 Sep; 190():224-228. PubMed ID: 30056321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C cure and medications for opioid use disorder improve health-related quality of life in patients with opioid use disorder actively engaged in substance use.
    Spaderna M; Kattakuzhy S; Kang SJ; George N; Bijole P; Ebah E; Eyasu R; Ogbumbadiugha O; Silk R; Gannon C; Davis A; Cover A; Gayle B; Narayanan S; Pao M; Kottilil S; Rosenthal E
    Int J Drug Policy; 2023 Jan; 111():103906. PubMed ID: 36384062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. M
    Martel-Laferrière V; Feaster DJ; Metsch LR; Schackman BR; Loignon C; Nosyk B; Tookes H; Behrends CN; Arruda N; Adigun O; Goyer ME; Kolber MA; Mary JF; Rodriguez AE; Yanez IG; Pan Y; Khemiri R; Gooden L; Sako A; Bruneau J
    Trials; 2022 Apr; 23(1):341. PubMed ID: 35461260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of a mixed-method approach to design an ED-based peer mHealth referral tool for HIV/HCV and opioid overdose prevention services.
    Knaub RJ; Evans J; Yang C; Roura R; McGinn T; Verschoore B; Ricketts EP; Rothman RE; Latkin CA; Hsieh YH
    Drug Alcohol Depend; 2022 Sep; 238():109585. PubMed ID: 35926299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Stigma is where the harm comes from": Exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs.
    Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
    Int J Drug Policy; 2021 Oct; 96():103238. PubMed ID: 33902968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic.
    Norton BL; Fleming J; Bachhuber MA; Steinman M; DeLuca J; Cunningham CO; Johnson N; Laraque F; Litwin AH
    Int J Drug Policy; 2017 Sep; 47():196-201. PubMed ID: 28811158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facilitating engagement of persons with opioid use disorder in treatment for hepatitis C virus infection via telemedicine: Stories of onsite case managers.
    Talal AH; Jaanimägi U; Davis K; Bailey J; Bauer BM; Dharia A; George S; McLeod A; Morton K; Nugent A; Zeremski M; Dinani A; Des Jarlais DC; Perumalswami PV; Tobin JN; Dickerson SS
    J Subst Abuse Treat; 2021 Aug; 127():108421. PubMed ID: 34134875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Video-Observed Treatment Strategy to Improve Adherence to Treatment Among Persons Who Inject Drugs Infected With Hepatitis C Virus: Qualitative Study of Stakeholder Perceptions and Experiences.
    Karasz A; Merchant K; Arnsten J; Feinberg J; Kim AY; Lum PJ; McKee MD; Mehta SH; Meissner P; Norton BL; Page K; Pericot-Valverde I; Singh R; Stein E; Taylor LE; Tsui JI; Wagner K; Litwin A
    J Med Internet Res; 2023 Jun; 25():e38176. PubMed ID: 37266986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Take Charge, Get Cured": Pilot testing a targeted mHealth treatment decision support tool for methadone patients with hepatitis C virus for acceptability and promise of efficacy.
    Jessop AB; Bass SB; Brajuha J; Alhajji M; Burke M; Gashat MT; Wellington C; Ventriglia N; Coleman J; D'Avanzo P
    J Subst Abuse Treat; 2020 Feb; 109():23-33. PubMed ID: 31856947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study protocol for Project I-Test: a cluster randomized controlled trial of a practice coaching intervention to increase HIV testing in substance use treatment programs.
    Frimpong JA; Parish CL; Feaster DJ; Gooden LK; Nelson MC; Matheson T; Siegel K; Haynes L; Linas BP; Assoumou SA; Tross S; Kyle T; Liguori TK; Toussaint O; Annane D; Metsch LR
    Trials; 2023 Sep; 24(1):609. PubMed ID: 37749635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.